Madrigal Pharmaceuticals Reports 2018 Fourth Quarter and Full Year Financial Results and Highlights
February 27, 2019 06:50 ET
|
Madrigal Pharmaceuticals, Inc.
CONSHOHOCKEN, Pa., Feb. 27, 2019 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today announced its fourth quarter and full year 2018 financial results and highlights: “Madrigal...
Phase 2 Results for Madrigal’s MGL-3196 in Non-Alcoholic Steatohepatitis (NASH) Presented during Presidential Plenary Clinical Session of The Liver Meeting® 2018
November 12, 2018 11:30 ET
|
Madrigal Pharmaceuticals, Inc.
-- Statistically significantly more NASH resolution in MGL-3196 as compared with placebo in a Phase 2 clinical trial support MGL-3196 as a first- and potentially best-in class thyroid hormone receptor...
ACC, AHA Release 2018 Guideline on the Management of Blood Cholesterol at AHA Scientific Sessions
November 10, 2018 12:55 ET
|
National Lipid Association
NLA among 12 organizations to co-author, endorse key document for reducing risk of atherosclerotic cardiovascular disease CHICAGO, Nov. 10, 2018 (GLOBE NEWSWIRE) -- The American College of...
Madrigal Pharmaceuticals Reports 2018 Third Quarter Financial Results and Highlights Upcoming Clinical Events
November 06, 2018 06:50 ET
|
Madrigal Pharmaceuticals, Inc.
CONSHOHOCKEN, Pa., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today announced its third quarter 2018 financial results and described upcoming clinical events: ...
Madrigal Pharmaceuticals Reports 2018 Second Quarter Financial Results and Reviews Key Clinical Achievements
August 07, 2018 06:50 ET
|
Madrigal Pharmaceuticals, Inc.
CONSHOHOCKEN, Pa., Aug. 07, 2018 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today announced its second quarter 2018 financial results and described recent clinical and...
Madrigal Pharmaceuticals Prices Public Offering of Common Stock
June 06, 2018 23:14 ET
|
Madrigal Pharmaceuticals, Inc.
CONSHOHOCKEN, Pa., June 06, 2018 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq:MDGL), a clinical-stage biopharmaceutical company focused on the development and commercialization of...
Madrigal Pharmaceuticals Announces Proposed Public Offering of Common Stock
June 05, 2018 16:10 ET
|
Madrigal Pharmaceuticals, Inc.
CONSHOHOCKEN, Pa., June 05, 2018 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq:MDGL), a clinical-stage biopharmaceutical company focused on the development and commercialization of...
Madrigal’s MGL-3196 Achieves Liver Biopsy Endpoints in Patients with Non-alcoholic Steatohepatitis (NASH) at 36 Weeks in Phase 2 Clinical Trial
May 31, 2018 06:50 ET
|
Madrigal Pharmaceuticals, Inc.
-- Statistically significantly more patients treated with MGL-3196 compared with placebo treated patients achieved a two point reduction in NAS (NAFLD activity score) on biopsy -- -- Statistically...
Madrigal Pharmaceuticals Reports 2018 First Quarter Financial Results and Reviews Key Clinical Achievements
May 08, 2018 06:50 ET
|
Madrigal Pharmaceuticals, Inc.
CONSHOHOCKEN, Pa., May 08, 2018 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today announced its first quarter 2018 financial results. During the first quarter, the Company...
Leading Cardiologist Dr. Neil Stone Secured as Speaker for the National Lipid Association Conference
July 18, 2016 12:47 ET
|
National Lipid Association
JACKSONVILLE, FL--(Marketwired - July 18, 2016) - Award-winning cardiologist, Neil J. Stone, MD, FACC, FNLA, will be the keynote speaker at the National Lipid Association (NLA) Clinical Lipid Update...